Jul 292010
Record Second Quarter Results Driven By Market Share Gains Across Major Markets
REVLIMID(R) Second Quarter Global Net Product Sales Increased 48% Y/Y
VIDAZA(R) Second Quarter Global Net Product Sales Increased 43% Y/Y
Non-GAAP Second Quarter Diluted Earnings Per Share Increased 50% Y/Y
SUMMIT, N.J., Jul 29, 2010 (BUSINESS WIRE) --
Celgene Corporation (NASDAQ: CELG):
2010 Second Quarter Financial Results Year-Over-Year
Non-GAAP Total Revenue Increased 36 Percent to $850 Million; GAAP Total Revenue $853 Million
Global REVLIMID Net Product Sales Increased 48 Percent to $587 Million
Global VIDAZA Net Product Sales Increased 43 Percent to $132 Million
Global THALOMID(R) Net Prod...